Drug Repurposing Market Size, Share, Trends & Forecast

The Drug Repurposing Market is gaining importance as pharmaceutical companies look for faster and more cost-effective approaches to developing new treatments. The market was valued at USD 39.2 billion in 2025 and is projected to reach USD 52.8 billion by 2035, growing at a 3.1% CAGR during 2026–2035. Patent expirations, rising development costs, and advances in computational drug discovery are supporting market expansion.

Drug repurposing allows existing medicines to be investigated for new therapeutic indications, reducing some of the time and cost associated with conventional drug discovery. Established safety information can provide developers with a valuable starting point when evaluating new applications for known compounds.

Oncology currently represents the largest therapeutic area, accounting for 40.1% of market revenue in 2024. Rare and orphan diseases are expected to grow particularly quickly, with computational screening and regulatory incentives helping researchers identify existing medicines that could address unmet medical needs.

Small-molecule drugs accounted for 69.4% of the market in 2024 because of their established safety profiles and relatively straightforward reformulation potential. North America leads the global market with a 48.7% revenue share, while Asia-Pacific is expected to record strong growth as clinical-trial infrastructure and pharmaceutical research capabilities expand.

Artificial intelligence is likely to become one of the most important influences on the future of drug repurposing. Machine learning, real-world evidence, network pharmacology, and multi-omics analysis can help researchers identify promising drug-indication relationships more efficiently, potentially accelerating the development of therapies for both common and rare diseases.

The Drug Repurposing Market is positioned for steady growth as pharmaceutical companies explore new uses for medicines that already have established development histories. The market was valued at USD 39.2 billion in 2025 and is expected to reach USD 52.8 billion by 2035, with a CAGR of 3.1% from 2026 to 2035. Rising R&D expenses and approaching patent expirations are encouraging companies to explore lifecycle-extension opportunities.

The approach can be particularly valuable when existing medicines have well-understood safety and pharmacological characteristics. Developers can then concentrate resources on demonstrating effectiveness in new patient populations or disease areas, although intellectual-property limitations and reimbursement uncertainty can still affect commercial decisions.

Rare and orphan diseases offer a promising growth opportunity because thousands of conditions have limited treatment options. Drug repurposing combined with AI-based screening can help researchers search large libraries of existing compounds for potential activity against rare disease pathways.

Pharmaceutical and biotechnology companies remain the largest end-user group, while CROs are becoming increasingly important as outsourcing grows. North America continues to lead the market, whereas Asia-Pacific offers significant future potential through expanding research infrastructure and clinical-trial capabilities.

Looking ahead, AI-driven discovery, multi-omics analysis, real-world evidence, and regulatory harmonization could reshape the competitive landscape. These technologies may make it easier to connect existing drugs with new disease targets, helping accelerate therapeutic innovation while improving access to treatments for areas with significant unmet medical needs.

Gain valuable insights through comprehensive industry analysis:

Clinical Trial Management System Market Volume

Clinical Trial Management System Market Forecast

Clinical Trial Management System Market Outlook

Cosmetic Dentistry Market Analysis

Cosmetic Dentistry Market Distribution